Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
| Step therapy |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- For new starts, the patient is not already on a stable maintenance dose of a GLP-1 agonist for at least 3 months
- Inadequate response, intolerance, or contraindication to metformin, or combination therapy with an A1C of 7.5% or greater
- Quantity limit: 30 tablets per 25 days, or 90 tablets per 75 days
- Continuation of therapy requires a demonstrated A1C reduction since starting a GLP-1 agonist
- Approval duration up to 36 months
Policy 3318-C. Source: GLP-1 Agonist Rybelsus PA with Limit Policy 3318-C UDR 05-2024, Pharmacy Clinical Policy Bulletins, Aetna Non-Medicare Prescription Drug Plan. payer prior-authorization policy. Verified August 27, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Aetna cover Rybelsus?
Aetna covers Rybelsus for type 2 diabetes, with prior authorization required through its pharmacy benefit manager, CVS Caremark. Approval needs a documented type 2 diabetes diagnosis plus either a failed, not tolerated, or contraindicated trial of metformin, or combination therapy with an A1C of 7.5% or greater. Rybelsus is not covered for weight loss, because it has no weight-loss indication. The weight-loss semaglutide is Wegovy, which is given by injection. This reflects the published policy verified August 2026.
What does Aetna require to approve Rybelsus?
For type 2 diabetes: true
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
